Mathew Geltzeiler

Dr. Mathew Geltzeiler


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
NFNyssa Fox Farrell
Nyssa Fox Farrell
JMJess C. Mace
Jess C. Mace
KDKara Y. Detwiller
Kara Y. Detwiller
RLRyan Li
Ryan Li
PAPeter E. Andersen
Peter E. Andersen
MGMathew Geltzeiler
Mathew Geltzeiler

28 November 2017 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
MPMichael J. Persky
Michael J. Persky
WAWilliam G. Albergotti
William G. Albergotti
TRTanya J. Rath
Tanya J. Rath
MKMark W. Kubik
Mark W. Kubik
SAShira Abberbock
Shira Abberbock
RFRobert L. Ferris
Robert L. Ferris
Objective: To compare positive margin rates between the 2 most common subsites of oropharyngeal transoral robotic surgery (TORS), the base of tongue (BOT) and the tonsil, as well as identify preoperative imaging characteristics that predispose toward positive margins.Study Design: Case series with chart review.Setting: Tertiary care referral center.Subjects and Methods: We compared the final and intraoperative positive margin rate between TORS resections for tonsil and BOT oropharyngeal squamous cell carcinoma (OPSCC), as well as the effect of margins on treatment. A blinded neuroradiologist examined the preoperative imaging of BOT tumors to measure their dimensions and patterns of spread and provided a prediction of final margin results.Results: Between January 2010 and May 2016, a total of 254 patients underwent TORS for OPSCC. A total of 140 patients who underwent TORS for T1/T2 OPSCC met inclusion criteria. A final positive margin is significantly more likely for BOT tumors than tonsil tumors (19.6% vs 4.5%, respectively, P =. 004) and likewise for intraoperative margins of BOT and tonsil tumors (35.3% vs 12.4%, respectively; P =. 002). A positive final margin is 10 times more likely to receive chemoradiation compared to a negative margin, controlling for extracapsular spread and nodal status (odds ratio, 9.6; 95% confidence interval, 1.6‐59.6; P =. 02). Preoperative imaging characteristics and subjective radiologic examination of BOT tumors did not correlate with final margin status.Conclusion: Positive margins are significantly more likely during TORS BOT resections compared to tonsil resections. More research is needed to help surgeons predict which T1/T2 tumors will be difficult to completely extirpate.

1 September 2018 in Oral Oncology
Verified
Journal Article
Open access
MGMathew Geltzeiler
Mathew Geltzeiler
MBMarnie Bertolet
Marnie Bertolet
WAWilliam Albergotti
William Albergotti
JGJohn Gleysteen
John Gleysteen
BOBrennan Olson
Brennan Olson
DCDaniel Clayburgh
Daniel Clayburgh
The American Joint Committee on Cancer, 8th edition (AJCC-8) contains a new staging system for human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC). Our study aim was to evaluate the effectiveness of the AJCC-8 relative to the AJCC 7th edition (AJCC-7). A retrospective chart review was performed on a multi-institutional, prospectively collected dataset from two tertiary referral centers. All patients had HPV+ OPSCC treated primarily with surgery. The prognostic value of AJCC-7 and AJCC-8 were compared for 5-year overall survival (OS) and disease-specific survival (DFS). AJCC-8 pathological staging effectively risk stratified patients, creating a Cox model with a better fit (lower Akaike’s Information Criterion, p < 0.0001) when compared to AJCC-7 pathological stages for both OS and DFS. The AJCC-8 pathologic staging did not produce a better fit than the AJCC-8 clinical staging (p = 0.15) for OS, however, AJCC-8 pathologic was more effective than AJCC-8 clinical for DFS (p < 0.0001). 76% of patients did not change their stage between clinical and pathologic AJCC-8 staging; 14% were upstaged by 1, <1% were upstaged by 2, 7% were downstaged by 1, and 3% downstaged by 2. The new AJCC-8 staging system represents a significant improvement over AJCC-7 for risk stratification into groups that predict overall survival and disease-specific survival of surgically treated HPV+ OPSCC patients. The AJCC- 8 pathologic staging system was not significantly better than the AJCC-8 clinical staging system for overall survival, however, the pathologic staging system was better than the clinical for disease free survival.

26 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KMKatie L. Melder
Katie L. Melder
MGMathew Geltzeiler
Mathew Geltzeiler
Sinonasal squamous cell carcinoma (SNSCC) and sinonasal undifferentiated carcinoma (SNUC) are two of the most common, high-grade malignancies of the sinonasal cavity. The standard of care for resectable lesions per the National Comprehensive Cancer Network (NCCN) guidelines includes surgical resection with negative margins plus adjuvant radiation therapy. However, surgery for locally advanced disease with both orbital and intracranial involvement is associated with significant morbidity and poor overall survival. Over the last decade, induction chemotherapy (IC) has emerged as part of a multimodal treatment strategy to optimize locoregional disease control and minimize substantial surgical morbidity such as orbital exenteration without compromising rates of overall survival. The response to IC both guides additional therapy and helps prognosticate a patient’s disease. This narrative review examines the data surrounding the management of patients with SNSCC and SNUC. The pros and cons of upfront surgical management plus adjuvant therapy will be explored, and the case for IC will be presented. The IC-specific regimens and treatment paradigms for SNSCC and SNUC will each be explored in detail. Organ preservation, treatment morbidity, and survival data will be presented, and evidence-based recommendations will be presented for the management of these patients.

17 June 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NBNoah E. Berlow
Noah E. Berlow
RRRishi Rikhi
Rishi Rikhi
MGMathew Geltzeiler
Mathew Geltzeiler
JAJinu Abraham
Jinu Abraham
MSMatthew Svalina
Matthew Svalina
CKCharles Keller
Charles Keller
Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when their disease inevitably progresses. To address the unmet clinical need for evidence-based therapy assignment when standard clinical approaches have failed, we have developed a probabilistic computational modeling approach which integrates molecular sequencing data with functional assay data to develop patient-specific combination cancer treatments. Tissue taken from a murine model of alveolar rhabdomyosarcoma was used to perform single agent drug screening and DNA/RNA sequencing experiments; results integrated via our computational modeling approach identified a synergistic personalized two-drug combination. Cells derived from the primary murine tumor were allografted into mouse models and used to validate the personalized two-drug combination. Computational modeling of single agent drug screening and RNA sequencing of multiple heterogenous sites from a single patient’s epithelioid sarcoma identified a personalized two-drug combination effective across all tumor regions. The heterogeneity-consensus combination was validated in a xenograft model derived from the patient’s primary tumor. Cell cultures derived from human and canine undifferentiated pleomorphic sarcoma were assayed by drug screen; computational modeling identified a resistance-abrogating two-drug combination common to both cell cultures. This combination was validated in vitro via a cell regrowth assay. Our computational modeling approach addresses three major challenges in personalized cancer therapy: synergistic drug combination predictions (validated in vitro and in vivo in a genetically engineered murine cancer model), identification of unifying therapeutic targets to overcome intra-tumor heterogeneity (validated in vivo in a human cancer xenograft), and mitigation of cancer cell resistance and rewiring mechanisms (validated in vitro in a human and canine cancer model). These proof-of-concept studies support the use of an integrative functional approach to personalized combination therapy prediction for the population of high-risk cancer patients lacking viable clinical options and without actionable DNA sequencing-based therapy.

16 December 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MGMathew Geltzeiler
Mathew Geltzeiler
MTMeghan Turner
Meghan Turner
RRRyan Rimmer
Ryan Rimmer
GZGeorge Zenonos
George Zenonos
AHAndrea Hebert
Andrea Hebert
EWEric W. Wang
Eric W. Wang